Marksans Pharma Share Price

NSE
MARKSANS •
BUY

1W Return

1M Return

6M Return

1Y Return

3Y Return

The current prices are delayed, login or Open Demat Account for live prices.
Start SIP in Marksans Pharma Ltd
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
148.27% Gain from 52W Low
22.4
TTM PE Ratio
Below industry Median
42.2
Price to Book Ratio
Below industry Median
7
Dividend yield 1yr %
Low in industry
0.2
TTM PEG Ratio
PEG TTM is much higher than 1
2.5

Marksans Pharma Ltd Key Financials

View more

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

Marksans Pharma Ltd Quarterly Revenue

Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
641.92 Cr
590.62 Cr
560.01 Cr
586.13 Cr
531.24 Cr

Marksans Pharma Ltd Yearly Revenue

Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
2227.83 Cr
1911.45 Cr
1532.69 Cr
1382.88 Cr
1134.54 Cr

Marksans Pharma Ltd Quarterly Net Profit/Loss

Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
97.76 Cr
89.07 Cr
77.64 Cr
82.96 Cr
83.85 Cr

Marksans Pharma Ltd Yearly Net Profit/Loss

Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
314.9 Cr
265.32 Cr
186.81 Cr
238.54 Cr
120.75 Cr

Marksans Pharma Ltd shareholding Pattern

Promoter
43.9%
Foreign Institutions
21.3%
Mutual Funds
3%
Domestic Institutions
4.1%
Public
30.7%
Promoter
43.9%
Foreign Institutions
18.6%
Mutual Funds
2.8%
Domestic Institutions
3.7%
Public
33.8%
Promoter
43.8%
Foreign Institutions
15.6%
Mutual Funds
4.2%
Domestic Institutions
5.1%
Public
35.4%
Promoter
43.8%
Foreign Institutions
15.6%
Mutual Funds
3.8%
Domestic Institutions
4.7%
Public
35.8%
Promoter
43.8%
Foreign Institutions
15.1%
Mutual Funds
3.2%
Domestic Institutions
4%
Public
37.1%
Promoter
43.8%
Foreign Institutions
14.9%
Mutual Funds
2.8%
Domestic Institutions
3.7%
Public
37.6%

Marksans Pharma Ltd Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
9
Bearish Moving Averages
7
5Day EMA
329.90
10Day EMA
332.10
12Day EMA
331.30
20Day EMA
325.70
26Day EMA
321.20
50Day EMA
304.60
100Day EMA
274.60
200Day EMA
233.00
5Day SMA
332.80
10Day SMA
339.00
20Day SMA
326.80
30Day SMA
314.40
50Day SMA
302.20
100Day SMA
270.10
150Day SMA
235.20
200Day SMA
215.70
Delivery & Volume

Delivery & Volume

PeriodCombined Delivery VolumeNSE+BSE Traded Volume
Day Rs
704768 Rs
2088216 Rs
Week Rs
722172 Rs
1873153 Rs
Month Rs
967726 Rs
3683730 Rs
Resistance & Support
322.33
Pivot
Resistance
First Resistance
328.27
Second Resistance
333.78
Third Resistance
339.72
Support
First Support
316.82
Second support
310.88
Third Support
305.37
Relative Strength Index
51.29
Money Flow Index
71.81
MACD
10.12
MACD Signal
12.84
Average True Range
14.04
Average Directional Index
30.45
Rate of Change (21)
7.80
Rate of Change (125)
107.45

Marksans Pharma Ltd Company background

Founded in: 1992
Managing director: Mark Saldanha
Marksans Pharma Limited was formerly incorporated as Tasc Pharmaceuticals Limited in April, 1982. Pursuant to the Scheme of Amalgamation, name of the Company was changed from Tasc Pharmaceuticals Limited to Marksans Pharma Limited with effect from 10th October, 2005. The Company primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulation. The Companys research and development facilities are located in Verna, Goa and R D center in Navi Mumbai.In 200405, the Company amalgamated with M/s. Marksans Pharma Limited (formerly M/s. Glenmark Laboratories Limited) pursuant to High Court order dated 19th August, 2005. As provided in the approved Scheme of Amalgamation, necessary shares were issued to the shareholders of the M/s. Marksans Pharma Limited (formerly M/s. Glenmark Laboratories Limited). The Company acquired majority stake in Nova Pharmaceuticals Australasia Private Limited in 2005 further, it acquired two companies, Bell Sons Company (Druggists) Limited and Relonchem Limited in the UK in 2008. The Company received first ANDA approval in the USA in 2011. It acquired TimeCap Laboratories Inc. in the US in 2015. The Company launched the CNSCerebella division in FY 201718. It launched soft gelatin capsules, a niche category, Launched two products and received CRL for 4 ANDAs for approval with the USFDA. The Company commissioned a new RD center at Navi Mumbai, apart from one in Goa in 201920. The Company acquired the business of Tevapharm India Private Limited relating to the manufacture and supply of pharmaceutical formulations in Verna, Goa as a going concern on a slump sale in April, 2023.
Read More

Marksans Pharma Ltd FAQs

Marksans Pharma Ltd shares are currently priced at 322.75 on NSE and 322.75 on BSE as of 12/10/2024 12:00:00 AM. Please be aware that stock prices are subject to continuous fluctuations due to various factors.

The past 1-year return of Marksans Pharma Ltd [MARKSANS] share was 97.82. The Marksans Pharma Ltd [MARKSANS] share hit a 1-year low of Rs. 130 and a 1-year high of Rs. 358.7.

The market cap of Marksans Pharma Ltd is Rs. 14625.86 Cr. as of 12/10/2024 12:00:00 AM.

The PE ratios of Marksans Pharma Ltd is 95.21 as of 12/10/2024 12:00:00 AM.

The PB ratios of Marksans Pharma Ltd is 11.33 as of 12/10/2024 12:00:00 AM

The Mutual Fund Shareholding was 3.02% at the end of 12/10/2024 12:00:00 AM.

You can easily buy Marksans Pharma Ltd shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
+91 -

personImage
Open Demat Account
+91 -